Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)

NCT00060671 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00060671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00060671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
Lead sponsor
CTI BioPharma
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2005
Completion date
January 31, 2006
Enrollment
800
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular, lymphoma, low-grade, lymphoma, mixed-cell, follicular, lymphoma, small cleaved-cell, follicular